TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04545580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
Study: NCT04545580
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1817080 will be taken twice daily orally as tablet(s)
Study: NCT01441232
Drug: LX4211
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of LX4211 administered as two 200 mg tablets
Study: NCT01441232
Drug: Januvia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Study: NCT01378585
Drug: DLBS1033
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 490 mg DLBS1033 daily
Study: NCT01378585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1 tablet daily
Study: NCT02109185
Drug: Nasonex® Nasal Spray, 50 μg/actuation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02109185
Drug: Nasonex® Nasal Spray Suspnsn, 50 μg/actuation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02109185
Drug: Placebo Nasal Spray, 50 μL/actuation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089401
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01608945
Drug: Hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day
Study: NCT02722083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, single dose, orally
Study: NCT03515668
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with same appearance/taste
Study: NCT02169427
Drug: OPC
Normalized name: DOPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug substance of 100 mg OPC was administered as 1 capsule.
Study: NCT00214201
Drug: Calcineurin inhibitor withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
Study: NCT03944317
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
Study: NCT00420771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
Study: NCT00641667
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
Study: NCT01041963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Study: NCT01227018
Drug: STA-9090
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02383212
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03800147
Drug: Mutaflor Suspension (E. coli Nissle 1917)
Normalized name: Duraflor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculation of Mutaflor Suspension (E. coli Nissle 1917)
Study: NCT02565368
Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration
Study: NCT02565368
Drug: CKD-395 0.5/1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration
Study: NCT03762317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
Study: NCT00124436
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01090661
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intravenous (IV) single dose
Study: NCT01090661
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous (SC) single dose
Study: NCT04396561
Drug: Paravertebral group (group P):
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels.
Study: NCT03578783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Study: NCT03578783
Drug: PSD502
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Study: NCT00242840
Drug: No intervention; Observational study
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01447147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules once daily
Study: NCT01447147
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX140-B capsules once daily (Group B)
Study: NCT01447147
Drug: CCX140-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX140-B capsules once daily (Group C)
Study: NCT01471652
Drug: Nutraceutical supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid
Study: NCT01471652
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid
Study: NCT04904952
Drug: N-acetylcysteine tablet 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Study: NCT04904952
Drug: Placebo tablet 600mg
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Study: NCT02190162
Drug: Tantum Verde® mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377103
Drug: testerone gel
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
Study: NCT01377103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01367990
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments).
Study: NCT03623529
Drug: LJPC-501 (angiotensin II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
Study: NCT03623529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Arm
Study: NCT00030732
Drug: Gemcitabine + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine + Capecitabine
Study: NCT03752437
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 IU of heparin
Study: NCT02212951
Drug: BIOD-531
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02212951
Drug: Humalog Mix 75/25
Normalized name: HumaLOG Mix 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02873351
Drug: carbidopa-levodopa 25-100 mg
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: included in arm description
Study: NCT02873351
Drug: placebo for carbidopa-levodopa 25-100 mg
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: included in arm description
Study: NCT02578706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231905
Drug: BI-Sifrol®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02961829
Drug: Sirtuin Histone deacetylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: latency disruption
Study: NCT00087867
Drug: SCIO-469
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 30-mg capsules three times daily
Study: NCT00622440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 48 weeks.
Study: NCT05125588
Drug: Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Study: NCT00545259
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04277338
Drug: SPECT
Normalized name: Spectrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Study: NCT01082068
Drug: XL147 (SAR245408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given orally once daily as tablets
Study: NCT01042106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5, 10, 20, 40 mg orally once daily
Study: NCT00196313
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet daily by mouth
Study: NCT03760042
Drug: Within-Subject Active vs Placebo Topical Applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
Study: NCT03760042
Drug: Within-Subject Active vs. Placebo Topical Applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
Study: NCT01664260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
Study: NCT00560170
Drug: Simvastatin (Zocor)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg of Simvastatin (n=20) orally per-day for 28 days
Study: NCT00560170
Drug: 10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
Study: NCT00010634
Drug: Connective Tissue Nutrient Formula
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199989
Drug: CapeOX（Capecitabine+Oxaliplatin）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
Study: NCT02660372
Drug: Imonogas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 120 mg in gel capsules
Study: NCT02660372
Drug: Espumisan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 40 mg in gel capsules
Study: NCT00647959
Drug: Doxycycline Tablets, 150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg, single dose fasting
Study: NCT00647959
Drug: Adoxa Tablets 150 mg
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg, single dose fasting
Study: NCT03210337
Drug: A-101 Topical Solution
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-101 Topical Solution
Study: NCT01821391
Drug: NDL-PDT
Normalized name: SYRINGE 1ML/NDL 20G 1IN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metvix natural daylight photodynamic therapy
Study: NCT01258686
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700mg thrice daily
Study: NCT01258686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 700mg thrice daily
Study: NCT01821391
Drug: c-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metvix conventional photodynamic therapy
Study: NCT01821391
Drug: placebo c-PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metvix placebo conventional photodynamic therapy
Study: NCT03350672
Drug: FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Study: NCT02481219
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01354314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule in the morning, three capsules in the evening
Study: NCT00414336
Drug: AMA1-C1/Alhydrogel + CPG 7909 Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02044094
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for hydromorphone administered via intramuscular injection during each challenge.
Study: NCT01740648
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
Study: NCT02321709
Drug: SAR113244
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT02321709
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study: NCT01809340
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
Study: NCT01809340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
Study: NCT00783107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871935
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia with remifentanil/propofol.
Study: NCT01871935
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia with sufentanil/propofol
Study: NCT04472910
Drug: Modified Folforinox (mFFX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
Study: NCT03854799
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Study: NCT03899922
Drug: Drugs inducing uveitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce uveitis
Study: NCT01730482
Drug: [14C] AT1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
Study: NCT00040326
Drug: antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: pharmacotherapy
Study: NCT01149018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Study: NCT00201630
Drug: Uroxatrol (drug)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02322866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching sarecycline tablets, taken orally at the same time each day.
Study: NCT00467753
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
Study: NCT00734877
Drug: M-VTD-PACE
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Study: NCT00734877
Drug: TT3-LITE Regimen (L-TT3)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Study: NCT03186742
Drug: Eplerenone 50 mg Tab
Normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 50 mg Tab once a day
Study: NCT00416221
Drug: Lexapro, an antidepressant medicine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02037230
Drug: MK-1775
Normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
Study: NCT03581500
Drug: Hyperpolarized Carbon C 13 Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02384200
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV (5 mg/kg)
Study: NCT03374709
Drug: Oxtellar XR 150Mg Extended Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxtellar XR
Study: NCT01258010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
Study: NCT02817464
Drug: TV-46046 - 400 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
Study: NCT02817464
Drug: TV-46046 - 200 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
Study: NCT02731105
Drug: Acnatac® Gel left face
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application
Study: NCT02731105
Drug: Epiduo® Gel right face
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application
Study: NCT02731105
Drug: Acnatac® Gel right face
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application
Study: NCT02731105
Drug: Epiduo® Gel left face
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application
Study: NCT01683786
Drug: Pegintron + Riba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
Study: NCT03193593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- Single injection of saline into Pectoralis Muscle
Study: NCT00924313
Drug: (C-11 Acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
Study: NCT03005717
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no